Temsirolimus metabolic pathways revisited

References

• Baker H, Sidorowicz A, Sehgal SN, et al. (1978). Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation. J Antibiot (Tokyo) 31:539–45.
   PubMed Web of Science ®Google Scholar
• Börnsen KO, Egge-Jacobsen W, Invernadi B, et al. (2007). Assessment and validation of the MS/MS fragmentation patterns of the macrolide immunosuppressant everolimus. J Mass Spectrom 42:793–802.
   PubMed Web of Science ®Google Scholar
• Cai P, Tsao R, Ruppen ME. (2007). In vitro metabolic study of temsirolimus: preparation, isolation, and identification of the metabolites. Drug Metab Dispos 35:1554–63.
   PubMed Web of Science ®Google Scholar
• Christians U, Jacobsen W, Serkova N, et al. (2000). Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immunosuppressants. J Chromatogr B 748:41–53.
   PubMed Web of Science ®Google Scholar
• Christians U, Sattler M, Schiebel HM, et al. (1992). Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin. Drug Metab Dispos 20:186–91.
   PubMed Web of Science ®Google Scholar
• Filler G, Bendrick-Peart J, Strom T, et al. (2009). Characterization of sirolimus metabolites in pediatric solid organ transplant recipients. Pediatr Transplant 13:44–53.
   PubMed Web of Science ®Google Scholar
• Galanis E, Buckner JC, Maurer MJ, et al. (2005). Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group study. J Clin Oncol 23:5294–304.
   PubMed Web of Science ®Google Scholar
• Hallensleben K, Raida M, Habermehl G. (2000). Identification of a new metabolite of macrolide immunosuppressant, like rapamycin and SDZ RAD, using high performance liquid chromatography and electrospray tandem mass spectrometry . J Am Soc Mass Spectrom 11:516–25.
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, et al. (2007). Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–81.
   PubMed Web of Science ®Google Scholar
• Jacobsen W, Serkova N, Hausen B, et al. (2001). Comparison of the in vitro metabolism of the immunosuppressants sirolimus and RAD. Transplant Proc 33:514–5.
   PubMed Web of Science ®Google Scholar
• Khan MS, Barratt DT, Somogyi AA. (2016). Impact of CYP2C8*3 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib. Xenobiotica 46:278–87.
   PubMed Web of Science ®Google Scholar
• Klawitter J, Nashan B, Christians U. (2015). Everolimus and sirolimus in transplantation-related but different. Expert Opin Drug Saf 14:1055–70.
   PubMed Web of Science ®Google Scholar
• Kuhn B, Jacobsen W, Christians U, et al. (2001). Metabolism of sirolimus and its derivative everolimus by cytochrome P450 3A4: insights from docking, molecular dynamics, and quantum chemical calculations. J Med Chem 44:2027–34.
   PubMed Web of Science ®Google Scholar
• MacPhee IA. (2012). Pharmacogenetic biomarkers: cytochrome P450 3A5. Clin Chim Acta 413:1312–7.
   PubMed Web of Science ®Google Scholar
• Mbatchi LC, Gassiot M, Pourquier P, et al. (2017). Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer. Cancer Chemother Pharmacol 80:653–9.
   PubMed Web of Science ®Google Scholar
• Morris RE. (1992). Sirolimus: antifungal, antitumor, antiproliferative, and immunosuppressive macrolides. Transplant Rev 5:39–87.
   Google Scholar
• Nef HM, Wiebe J, Foin N, et al. (2017). A new novolimus-eluting bioresorbable coronary scaffold: present status and future clinical perspectives. Int J Cardiol 227:127–33.
   PubMed Web of Science ®Google Scholar
• Peralba JM, DeGraffenried L, Friedrichs W, et al. (2003). Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 9:2887–92.
   PubMed Web of Science ®Google Scholar
• Schreiber SL. (1991). Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 251:283–7.
   PubMed Web of Science ®Google Scholar
• Schuler W, Sedrani R, Cottens S, et al. (1997). SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 64:36–42.
   PubMed Web of Science ®Google Scholar
• Sehgal SN, Baker H, Vézina C. (1975). Sirolimus (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 28:727–32.
   PubMed Web of Science ®Google Scholar
• Sehgal SN, Molnar-Kimber K, Ocain TD, et al. (1994). Rapamycin: a novel immunosuppressive macrolide. Med Res Rev 14:1–22.
   PubMed Web of Science ®Google Scholar
• Streit F, Christians U, Schiebel HM, et al. (1996). Structural identification of four metabolites of the macrolide immunosuppressant sirolimus after in vitro metabolism by electrospray-MS/MS. Drug Metab Dispos 24:1272–8.
   PubMed Web of Science ®Google Scholar
• Strom T, Haschke M, Bendrick-Peart J, et al. (2007). Everolimus metabolite patterns in the blood of kidney transplant patients. Ther Drug Monit 29:592–9.
   PubMed Web of Science ®Google Scholar
• Strom T, Shokati T, Klawitter J, et al. (2011). Structural identification of SAR-943 metabolites generated by human liver microsomes in vitro using mass spectrometry in combination with analysis of fragmentation patterns. J Mass Spectrom 46:615–24.
   PubMed Web of Science ®Google Scholar
• Vézina C, Kudelski A, Sehgal SN. (1975). Sirolimus (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 28:721–6.
   PubMed Web of Science ®Google Scholar
• Wang PC, Chan KW, Schiksnis RA, et al. (1994). High-performance liquid chromatographic isolation, spectroscopic characterization, and immunosuppressive activities of two sirolimus degradation products. J Liq Chromatogr 17:3383–92.
   Web of Science ®Google Scholar
• Zanger UM, Schwab M. (2013). Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103–41.
   PubMed Web of Science ®Google Scholar